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MiceHDL has important immunomodulatory properties, including the attenuation of lipopolysaccharide (LPS)-induced
inﬂammatory response. As lecithin–cholesterol acyltransferase (LCAT) is a critical enzyme in the maturation of
HDL we investigated whether LCAT-deﬁcient (Lcat−/−) mice present an increased LPS-induced inﬂammatory re-
sponse. LPS (100 μg/kg body weight)-induced cytokine response in Lcat−/− mice was markedly enhanced and
prolonged compared to wild-type mice. Importantly, reintroducing LCAT expression using adenovirus-mediated
gene transfer reverted their phenotype to that of wild-type mice. Ex vivo stimulation of whole blood with LPS (1–
100 ng/mL) showed a similar enhanced pro-inﬂammatory phenotype. Further characterization in RAW264.7mac-
rophages in vitro showed that serum and HDL, but not chylomicrons, VLDL or the lipid-free protein fraction of
Lcat−/−mice, had a reduced capacity to attenuate the LPS-induced TNFα response. Analysis of apolipoprotein com-
position revealed that LCAT-deﬁcient HDL lacks signiﬁcant amounts of ApoA-I and ApoA-II and is primarily com-
posed of ApoE, while HDL from Apoa1−/−mice is highly enriched in ApoE and ApoA-II. ApoA-I-deﬁciency did not
affect the capacity of HDL to neutralize LPS, though Apoa1−/−mice showed a pronounced LPS-induced cytokine re-
sponse. Additional immunophenotyping showed that Lcat−/− , but notApoa1−/−mice, havemarkedly increased cir-
culating monocyte numbers as a result of increased Cd11b+Ly6Cmed monocytes, whereas ‘pro-inﬂammatory’
Cd11b+Ly6Chi monocytes were reduced. In line with this observation, peritoneal macrophages of Lcat−/− mice
showed a markedly dampened LPS-induced TNFα response. We conclude that LCAT-deﬁciency increases LPS-
induced inﬂammation in mice due to reduced LPS-neutralizing capacity of immature discoidal HDL and increased
monocyte number.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
High-density lipoprotein (HDL) is a heterogeneous mixture of lipo-
protein particles that differ in size, shape, lipid and apolipoprotein com-
position. HDL is continuously remodeled by lipolytic enzymes and lipid
transporters but also by exchanging lipids and apolipoproteins withlipoprotein A-II; ApoE, apolipo-
scence protein; AdLCAT, adeno-
macrophage colony stimulating
L-12p70, interleukin 12 subunit
, lecithin–cholesterol acyltrans-
tor alpha; TRL, triglyceride-rich
l School, Rio, Achaia, PC. 26500,
os).other lipoproteins and tissues [1,2]. Mature HDL particles consist of a
hydrophobic core containing cholesteryl esters and triglycerides and a
surface lipid monolayer composed mainly of phospholipids and free
cholesterol, where amphipathic apolipoproteins are embedded. Apoli-
poprotein (Apo) A-I and ApoA-II are the two main protein components
of HDL, but also other apolipoproteins and enzymes such as apolipopro-
tein E (ApoE) and lecithin–cholesterol acyltransferase (LCAT), are asso-
ciated with HDL [1].
HDL possesses several important biological functions [3]. Its best char-
acterized function is its role in ‘reverse cholesterol transport’. HDL takes
up cholesterol from theperipheral tissues, including the vesselwall, to de-
liver it to the liver for excretion into the bile. In addition, HDL has the abil-
ity to alleviate inﬂammation and suppress immune activation, which is
critical for the prevention of atherosclerosis and coronary heart disease
[4]. Indeed, the anti-inﬂammatory properties of HDL contribute signiﬁ-
cantly to its atheroprotective potential as persistent low-grade inﬂamma-
tion is a key factor in the development and progression of atherosclerosis.
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ride (LPS) appear to sustain a non-resolving mild inﬂammation. As a
consequence, low-grade endotoxemia may skew the immune milieu
of the host towards a low-grade pro-inﬂammatory state, which
ultimately leads to sepsis [5], a major cause of death in intensive
care patients. LPS, the major pathogenic mediator of Gram-negative
sepsis, is mainly responsible for the observed mortality through its
cytotoxic functions [6]. LPS is recognized by the Toll-like receptor 4
(TLR4) on the cell surface of mainly monocytes and macrophages
[7], and after binding a signaling cascade initiates the secretion of
an array of cytokines, including TNFα. To prevent damage to tissues
and organs by the LPS-mediated inﬂammatory response, the host has
developed several control mechanisms that include inhibitory LPS-
binding proteins [8] and plasma lipoproteins, such as HDL [9].
In humans with severe sepsis plasma HDL-C levels decrease
rapidly [10]. Concomitantly, structural alteration of HDL, including
a signiﬁcant increase in serum amyloid-A (SAA) levels, takes place
at the beginning of sepsis. During recovery, plasma HDL-C levels
are restored and SAA is slowly replaced by ApoA-I and other apoli-
poproteins [10]. Low HDL-C levels inversely correlate with the
severity of septic disease and associate with a magniﬁed systemic
inﬂammatory response [11], although it is difﬁcult to distinguish
whether changes in plasma lipoproteins simply mirror the severity
of disease or they directly alter the host response to inﬂammation.
In healthy individuals, low HDL-C levels are associated with
heightened inﬂammatory response on endotoxin challenge com-
pared to subjects with normal or high HDL-C levels [12], without
differences in the HDL proteome [13]. In agreement with clinical
data, Apoa1−/− mice, which lack classical HDL, exhibit a lower
LPS-neutralizing capacity in serum compared with serum from
control mice [14], whereas transgenic overexpression of human
ApoA-I moderately improves survival conﬁrming that HDL eleva-
tion may protect against septic death [15].
Several mechanisms have been described to contribute to the HDL-
mediated protection. It has been proposed that plasma lipoproteins in-
cluding HDL bind and neutralize Gram-positive bacterial lipoteichoic
acid (LTA) [16] as well as Gram-negative bacterial LPS [17]. In addition,
HDLmay protect against sepsis by enabling LPS clearance via its interac-
tion with Scavenger Receptor BI (SR-BI) [18]. In fact, almost all LPS is
present as an LPS–HDL complex in blood [19,20]. A third mechanism
includes the release of macrophage-bound LPS by HDL that in turn
reduces macrophage activation [21]. Another potential mechanism is
the facilitation of an early inﬂammatory response to Gram-negative
bacteria via suppression of the inhibitory activity of LBP [22].
LCAT is a critical enzyme in the maturation of HDL by mediating
the conversion of discoidal to spherical HDL [23]. However, the role
of LCAT or LCAT-mediated maturation of HDL in the neutralizing
capacity of HDL is unknown. Therefore, in the present study we
investigated whether lack of mature HDL in Lcat−/− mice increases
the LPS-induced inﬂammatory response, and compared the response
to that of Apoa1−/− mice. We show that Lcat−/− mice on one hand
have an increased overall systemic pro-inﬂammatory response as a
result of decreased LPS-neutralizing capacity, but on the other
hand have a reduced pro-inﬂammatory monocyte/macrophage phe-
notype that partly opposes its pro-inﬂammatory effect. Marked
differences were observed between Apoa1−/− and Lcat−/− mice
suggesting that qualitative alterations in HDL may inﬂuence inﬂam-
matory response through distinct mechanisms.
2. Materials and methods
2.1. Animals
Lcat−/−mice (kinddonation fromProf. Silvia Santamarina-Fojo) and
Apoa1−/− and C57BL/6mice (both from Jackson Laboratory, Bar Harbor,
Maine, USA) were bred in the animal facility of the University of Patras.Malemice of 10–16weeks of agewere used for experiments.Micewere
allowed unrestricted access to food and water under a 12 h light/dark
cycle. At the end of each experiment, mice were sacriﬁced and plasma
and tissue samples were collected, snap-frozen in liquid nitrogen, and
stored at−80 °C. All animal studieswere governed by the EUguidelines
of the Protocol for the Protection andWelfare of Animals and conducted in
accordance with the Declaration of Helsinki and authorized by the
appropriate committee of the Laboratory Animal Center of the Universi-
ty of Patras Medical School and the Veterinary Authority of the Prefec-
ture of Western Greece.
2.2. In vivo LPS stimulation
Mice were injected intravenously with Escherichia coli LPS 055:B5
(Sigma, St. Louis, MO,USA; 100 μg/kg bodyweight) and PBS as a vehicle.
Before the injection (t = 0) and at the indicated time points, blood
samples were taken from the tail vein into EDTA-capillary tubes and
stored on ice. Plasma was isolated and plasma cytokine levels were
determined using the Bio-Plex Mouse Cytokine Group I 13-plex Assay,
with Magnetic Beads (Bio-Rad, Hercules, CA, USA). Final data were ob-
tained and analyzed via the Bio-plex 3D Suspension array system
(Bio-Rad). Absolute quantitation was achieved via cytokine speciﬁc
standards for curve creation provided with the kit. TNFαwas also mea-
sured with ELISA using the commercially available mouse TNF alpha
ELISA kit (eBioscience, San Diego, USA).
2.3. In vivo AdLCAT administration
The ampliﬁcation andexpansion of the attenuated recombinant con-
trol adenovirus AdGFP and the LCAT-expressing adenovirus AdLCAT,
have been described previously [24]. Typically, titers of approximately
2 × 1010 pfu/mL were obtained for each virus preparation. Lcat−/−
mice were injected with either AdGFP or AdLCAT adenovirus at a low
dose of 5 × 108 pfu. As an additional control, WT mice were injected
with AdGFP. Three days post-infection, samples of blood were collected
for baseline plasma cholesterol and TNFα levels. Immediately after, all
mice were injected intravenously with LPS (100 μg/kg body weight).
TNFα response was monitored in plasma at the indicated time points
as described above.
2.4. Western blot analysis
Western blot analysis of ApoA-I, ApoE and ApoA-II in HDL fraction
was performed as described previously [24]. As primary antibodies a
goat anti-human ApoA-I antibody (Biodesign International, Saco, ME,
USA), a goat anti-human ApoE antibody (Biodesign International), and
a goat-anti-human ApoA-II antibody (Biodesign International) were
used, and as secondary antibody a rabbit anti-goat antibody (Santa-
Cruz, Dallas, TX, USA).
2.5. Ex vivo whole blood LPS stimulation
Whole blood was collected into EDTA-capillary tubes, diluted 1:25
with serum-free DMEM medium and plated onto 24-well plates. The
blood was incubated for 18 h with or without LPS (1 and 10 ng/mL)
and subsequently transferred into a tube and centrifuged at 1000 rpm
for 5 min for removal of the blood cells. TNFα levels were quantiﬁed
by ELISA as described above.
2.6. Fractionation of serum lipoproteins by density gradient ultra
centrifugation
For the isolation of serum, blood from unfasted mice was collected
into Eppendorf tubes on ice. Subsequently, blood sampleswere incubat-
ed for 15 min at 37 °C to activate clotting and centrifuged for 10 min at
7000 rpm. Pooled serum per group was fractionated by KBr density
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chylomicrons and VLDL)were isolated from the top fractionwith a den-
sity of 1.006 g/L, the HDL from the 1.063 g/L fraction, and the
lipoprotein-free proteins from the bottom fraction with a density of
1.21 g/L.
2.7. Lipid and total protein quantitation in plasma, serum and lipoprotein
fractions
Total cholesterol (TC; Cholesterol FS kit; DiaSys Diagnostic Systems
GmbH, Holzheim, Germany), free cholesterol (FC; Free Cholesterol E
Kit; Wako, Richmond, VA, USA) and phospholipids (PL; Phospholipid
C determination kit; Wako) were determined spectrophotometrically
according to manufacturers' instructions. Total protein in lipoprotein
fractions or cell lysates was measured by the Lowry assay using the
DCTM Protein Assay Kit (Bio-Rad). The lipid content of the HDL fraction
are expressed as mg/dL of the original serum sample.
2.8. FACS analysis for phenotyping of monocytes
Blood from WT, Lcat−/− and Apoa1−/− mice was collected into
EDTA-capillary tubes. 25 μLwere transferred in a new tube and incubat-
ed on ice with 0.5 μg of FCR III/II blocking antibody (anti-mouse CD16/
32; eBioscience) for 15 min. Cells were washed and incubated with
0.25 μg of anti-mouse CD11b-FITC (eBioscience), 0.125 μg of anti-
mouse Ly6C APC (eBioscience), for 20 min. Afterwards, erythrocytes
were lysed with an ammonium chloride-containing lysis buffer. At
least twenty thousand events were acquired using a BD FACSCalibur™
ﬂow cytometer (Becton-Dickinson, USA) and data were analyzed
using Flowjo software (Tree Star). All living cells were gated from the
FSC/SSC scatter plot and indicated as total white blood cells (WBC).
From these total WBC we plotted CD11b+ versus Ly6C cells and deter-
mined the percentage of Ly6Clo, Ly6Cmed, and Ly6Chi within CD11b+
monocytes and expressed them as percentage of total WBC.
2.9. In vitro macrophage LPS stimulation
RAW 264.7 cells, a murine macrophage cell line, were seeded onto
96-well plates (60 × 103 cells/well) and cultured overnight at 37 °C in
DMEM containing 10% FBS and 1% pen/strep. For the isolation of prima-
ry peritoneal macrophages, mice were initially injected intra-
peritoneally with 1 mL of 3% (w/v) Brewer's thioglycollate medium.
Four days later, peritoneal macrophages were obtained by peritoneal
lavage with 10 mL ice-cold sterile PBS using a 25G needle. Following 2
cycles of washing with ice-cold sterile PBS, cells were resuspended
into 1 mL DMEM culture medium containing 10% fetal bovine serum
(FBS) and 1% pen/strep and plated onto 24 well plates (8 × 105 cells/
well). The next day, macrophages were washed with serum-free
DMEMmedium and incubated with LPS (1–100 ng/mL) that was prein-
cubated (30 min 37 °C) with or without serum or lipoprotein fractions
from WT, Lcat−/− and Apoa1−/− mice in DMEM supplemented with
0.1% human serum albumin (4 h at 37 °C) [25,26]. As controls, cells
were incubated with human serum albumin as vehicle and serum or
lipoprotein fractions at the highest concentration used. The mediumTable 1
Sequence of oligonucleotide primers used in the qRT-PCR analysis.
Mouse gene Marker for Forward seq
F4/80 Common macrophage 5′- CTTTGGC
Cd68 Common macrophage 5′- ATCCCCA
Mcp1 Common-monocyte attraction 5′- GCATCTG
Mrc1 M2 5′- GAGAGC
Cd163 M2 5′- CTCAGGA
Arg1 M2 5′- GGTTCTG
Rplp0 Housekeeping gene 5′- GGACCCG
Rpl13a Housekeeping gene 5′- CTGGTACwas collected and TNFα was determined in the cultured medium by
ELISA as described above. For the experiments involving peritoneal
macrophages protein content of each cell lysate was determined as
described above and the TNFα levels were expressed as ng/mg cell
protein.
2.10. Quantitative real-time PCR (qRT-PCR)
Total RNA was extracted from fresh frozen liver tissue using the
TRIZOL reagent (Invitrogen, Carlsbad, CA, USA) according to
manufacturer's instructions. Reverse transcription was performed
using the PrimeScriptTM RT reagent kit (Takara Bio Inc., Otsu,
Shiga, Japan). Real-Time PCR for F4/80, Cd68, Mcp1, Mrc1, Cd163,
Arg1 and the housekeeping genes Rpl13A, Rplp0 was performed in
a MicroAmp® 96-well reaction plate (Applied Biosystems, Foster
City, CA, USA) using the KAPA SYBR® FAST Universal qPCR kit
(Kapa Biosystems, Woburn, MA, USA), in an Applied Biosystems®
StepOne™ cycler (Applied Biosystems). Primers (Invitrogen-Life
Technologies, Renfrewshire, Scotland) used are shown in Table 1.
Data were normalized for Rpl13A, Rplp0 expression.
2.11. Statistical analysis
Data are reported asmean± SEM. * and # indicate p b 0.05, ** and ##
indicate p b 0.01, and ### and *** indicate p b 0.001. Non-signiﬁcant dif-
ferences are not indicated. n indicates the number of animals tested in
each experiment. Statistical analyses between 2 groups were assessed
using unpaired two-tailed Student's t-test and between 3 groups using
one-way ANOVA with a Bonferroni's post-hoc test. GraphPad Prism 5
was used for these statistical analyses.
3. Results
3.1. Baseline HDL-lipid and apolipoprotein characterization of HDL
Baseline serum lipid and HDL-lipid levels of WT, Lcat−/− and
Apoa1−/− mice are shown in Table 2. As expected Lcat−/− mice carry
only minimal amounts of cholesteryl esters (CE) in their HDL and the
predicted relative size of HDL is also much smaller as compared to
HDL of WT mice. The HDL-lipid composition of Apoa1−/− mice shows
less pronounced differences with the HDL of WT mice. To examine the
qualitative differences in the protein composition of HDL among the 3
genotypeswe performedwestern blot analysis for the threemost abun-
dant HDL apolipoproteins, i.e. ApoA-I, ApoE and ApoA-II. HDL of WT
mice consists almost exclusively of ApoA-I, while LCAT-deﬁcient HDL
contains barely detectable ApoA-I, but primarily ApoE (Fig. 1). ApoA-I-
deﬁcient HDL consists mainly of ApoE and to a lesser extent of ApoA-II.
3.2. LCAT-deﬁciency enhances the LPS-induced inﬂammatory response
in vivo
To assess the potential effects of these qualitative alterations in HDL
on its anti-inﬂammatory properties, we ﬁrst examined whether LCAT-
deﬁciency modulates the systemic inﬂammatory response in vivouence Reverse sequence
TATGGGCTTCCAGTC 5′- GCAAGGAGGACAGAGTTTATCGTG - 3′
CCTGTCTCTCTCA - 3′ 5′- TTGCATTTCCACAGCAGAAG - 3′
CCCTAAGGTCTTCA - 3′ 5′- TTCACTGTCACACTGGTCACTCCTA - 3′
CAAGCCATGAGAAC - 3′ 5′- GTCTGCACCCTCCGGTACTA - 3′
AACCAATCCCAGA - 3′ 5′- CAAGAGCCCTCGTGGTAGAC - 3′
GGAGGCCTATCTTACA - 3′ 5′- TCTTCACCTCCTCTGCTGTCTTC - 3′
AGAAGACCTCCTT - 3′ 5′- GCACATCACTCAGAATTTCAATGG - 3′
TTCCACCCGACCTC - 3′ 5′- GGATCCCTCCACCCTATGACA - 3′
Table 2
Serum and HDL lipid levels.
WT Lcat−/− Apoa1−/−
Serum lipid levels
TC (mg/dL) 64.85 ± 3.27 30.21 ± 1.19 38.40 ± 0.90
PL (mg/dL) 166.23 ± 1.78 82.50 ± 1.41 91.76 ± 1.30
TG (mg/dL) 58.68 ± 2.80 101.80 ± 3.08 37.47 ± 1.80
Serum HDL-lipid levels
HDL–TC (mg/dL) 38.02 ± 0.04 3.38 ± 0.04 18.26 ± 0.05
HDL–FC (mg/dL) 10.33 ± 0.05 2.70 ± 0.18 5.39 ± 0.13
HDL–CE (mg/dL) 27.69 ± 0.02 0.68 ± 0.46 12.87 ± 0.04
HDL–PL (mg/dL) 16.98 ± 0.08 4.80 ± 0.17 14.00 ± 0.10
HDL–TG (mg/dL) 1.78 ± 0.61 2.23 ± 0.30 1.25 ± 0.19
HDL–Protein (mg/dL) 195 ± 3 47 ± 4 112 ± 3
Relative HDL size
(TG + CE)/(PL + TC)
1.08 0.39 0.73
Serum lipid levels are presented as mean ± SEM, n = 5 mice per genotype. Serum HDL-
lipid levels are presented as mean ± SEM, n = 3 technical replicates of isolated HDL
from pooled serum of 5 mice per genotype. CE, cholesteryl esters; FC, free cholesterol;
PL, phospholipids; TC, total cholesterol; TG, triglycerides.
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Based on cytokine proﬁle, Lcat−/− mice showed a clear pro-
inﬂammatory response when compared to their WT counterparts. The
pro-inﬂammatory cytokines TNFα, IFNγ, IL-2, IL-12p70, the growth factor
GM-CSF and the anti-inﬂammatory cytokine IL-10 were all signiﬁcantly
elevated after LPS injection (Fig. 2 A–F). Interestingly, Lcat−/−mice also
display a prolonged response that fails to return to baseline levels even
240 min after initial challenge with LPS. This is a strikingly different re-
sponse fromWTmice that showa transient and less pronounced increase
in their LPS-induced cytokine response, with several cytokines returning
to baseline levels within the timeframe of the study. Interestingly, the en-
hanced LPS-induced TNFα response of Lcat−/−mice appears comparable
to that of Apoa1−/−mice that are known to develop a poor response to
LPS (Fig. 2 G–H).
We next validated whether adenoviral expression of human LCAT
could restore the LPS-induced pro-inﬂammatory phenotype in Lcat−/−
mice. We ﬁrst conﬁrmed that transfection of Lcat−/−mice with AdLCAT
indeed normalized the plasma lipoprotein proﬁle to a similar extent as
observed in WT mice (Table 3). Importantly, reintroducing LCAT in
Lcat−/−mice normalized the LPS-induced TNFα response to a similar ex-
tent as observed in WT mice (Fig. 2 I).
Since LCAT is a plasma enzyme that primarily modiﬁes circulating
lipoproteins, we next investigated if the apparent changes in the inﬂam-
matory proﬁle of Lcat−/−mice are due to changes in blood. Indeed, the
enhanced pro-inﬂammatory response was retained in whole blood of
Lcat−/− mice since ex vivo stimulation of whole blood of Lcat−/− mice
with LPS resulted in a markedly increased LPS-induced TNFα response
thatwas even greater than the response observed inwhole blood isolated
from Apoa1−/−mice (Fig. 3).
3.3. LCAT-deﬁcient serum and HDL enhance the LPS-induced pro-
inﬂammatory response in vitro
The LPS-induced inﬂammatory response bywhole bloodmay be de-
termined by both serum components able to modulate inﬂammatoryTable 3
Total and esteriﬁed plasma cholesterol of WT and Lcat−/−mice treated with AdGFP and Lcat−
Group TC day 0 (mg/dL) TC day 3 (mg/dL) % change P (day 0
(A) WT + AdGFP 59.4 ± 5.2 58.3 ± 6.2 −2% 0.90
(B) Lcat−/−+ AdGFP 23.4 ± 4.1 17.7 ± 2.4 −32% 0.26
(C) Lcat−/−+ AdLCAT 25.7 ± 2.9 51.2 ± 5.8 +50% 0.01
P (A vs B) b0.001 b0.001
P (A vs C) b0.01 0.43
P (B vs C) 0.68 b0.01
% change refers to changes in plasma lipid levels prior and 3 days following infection. Data
cholesterol.response, such as lipoproteins, as well as by the number and activity
of monocytes, the effector cells. To characterize the effects of serum
and its components on LPS inﬂammation, RAW 264.7 macrophages
were stimulated with LPS in the presence of serum from Lcat−/−mice
as well as serum from WT and Apoa1−/− mice, as controls. LCAT-
deﬁcient serum clearly stimulated the LPS-induced TNFα response at
low concentrations of serum (≤0.1%) and only at high concentrations
(10%) was able to neutralize this response (Fig. 4 A). This impaired
LPS-neutralizing capacity of LCAT-deﬁcient serum was comparable
to the one observed with ApoA1-deﬁcient serum (Fig. 4 B). As ex-
pected serum from WT mice caused a dose-dependent reduction in
LPS-induced TNFα response that was apparent even at very low
concentrations.
To further dissect which serum components are responsible for the
observed effect, we fractionated plasma by KBr density gradient ultra-
centrifugation and investigated the LPS-neutralizing capacity of various
serum lipoproteins and the lipid-free protein fraction. As expected, HDL
fromWTmice neutralized LPS-induced inﬂammation. This neutralizing
effect was abolished when HDL from LCAT-deﬁcient mice was used
(Fig. 4 C). These data may suggest that Lcat−/− mice not only lack
mature HDL in their serum but also that the LPS-neutralizing capacity
still present in the remaining discoidal HDL may be impaired. Further
analysis indicated that the increased LPS-induced inﬂammatory
response of the LCAT-deﬁcient serum could not be explained by an im-
paired response of triglyceride-rich lipoproteins (TRL; chylomicrons
and VLDL) and the lipid-free serum proteins (Fig. 4 C). Surprisingly,
the TRL fraction of Lcat−/− serum was rather anti-inﬂammatory
suggesting that the pro-inﬂammatory properties of Lcat−/− plasma
are solely due toHDL. Similar but less pronounced resultswere obtained
when lipoproteins from Apoa1−/− serum were tested, with the excep-
tion of TRLs which failed to neutralize LPS (Fig. 4 D).
A possible explanation is that LCAT serves as a bridging molecule
that binds LPS onto HDL, thus Lcat−/− HDL fails to neutralize LPS in cir-
culation due to lack of LCAT. To test this possibility, we incubated LCAT-
deﬁcient HDL with puriﬁed LCAT protein and measured its anti-
inﬂammatory potential. Our data show that incubation of LCAT with
Lcat−/− HDL did not affect LPS-induced pro-inﬂammatory response
(Fig. 4 E), excluding a direct effect of LCAT protein as a bridging mole-
cule, on LPS-induced inﬂammation.
3.4. LCAT-deﬁciency associates with high monocyte numbers, but reduced
inﬂammatory status of monocytes and macrophages
To characterize the possible role of circulating monocytes and tissue
macrophages to the observed pro-inﬂammatory phenotype in vivo, we
investigated circulating levels of CD11b-positive (CD11b+) monocytes
and their inﬂammatory status, i.e. Ly6C expression.We found increased
numbers of circulating CD11b+/Ly6C+ monocytes (Fig. 5 A) in Lcat−/−
mice that were unexpectedly due to an increase in normal circulating
Ly6Cmed monocytes, and not in newly recruited Ly6Chi monocytes
(Fig. 5 B,D–F). Increased number of Ly6Chi monocytes is a usual marker
of a heightened systemic inﬂammatory condition of the mouse [27]. In-
deed, the Ly6Chi/Ly6med ratio was decreased by 2.5-fold in Lcat−/−mice
(Fig. 5 C), compared to WT counterparts. Interestingly, in line with this/−mice treated with AdLCAT.
vs day 3) CE day 0 (mg/dL) CE day 3 (mg/dL) % change P (day 0 vs day 3)
43.4 ± 4.6 39.9 ± 4.4 −9% 0.60
11.1 ± 3.2 7 ± 2 −59% 0.31
17 ± 3.2 39.6 ± 5.3 +57% 0.01
b0.001 b0.001
b0.01 0.96
0.24 b0.001
are presented as mean ± SEM, n = 5–6 mice per group. CE, cholesteryl ester; TC, total
Table 4
Summary of lipid- and inﬂammation-related features of WT, Lcat−/− and Apoa1−/−mice.
WT Lcat−/− Apoa1−/−
General features
HDL Mature Immature Mature/atypical
ApoA-I on HDL √ × ×
ApoE on HDL × √ √
ApoA-II on HDL × × √
In vivo cytokine response to LPS Normal ↑ ↑
Pro-inﬂammatory features
Ex vivo cytokine response to LPS of
whole blood
Normal ↑↑ ↑
In vitro LPS-neutralizing potential of
serum
Normal ↓↓ ↓
In vitro LPS-neutralizing potential of
HDL
Normal ↓↓ Normal
Blood monocyte Normal ↑↑ Normal
Anti-inﬂammatory features
Blood Ly6Chi/med monocyte ratio Normal ↓↓ Normal
CD11b expression Normal ↓↓ Normal
In vitromacrophage response to LPS Normal ↓↓ ↑
↑↑ indicates large increase compared to WT group; ↑ indicates moderate increase
compared to WT group; ↓↓ indicates large decrease compared to WT group; ↓ indicates
moderate decrease compared to WT group.
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served a consistent reduction in CD11b expression (evident by reduced
Mean Fluorescence Intensity) in all three monocyte populations of
Lcat−/− mice (Fig. 5 G–J). To our surprise, circulating monocytes of
Apoa1−/− mice showed a distinctly different pattern. The total mono-
cyte number was slightly increased compared to WT mice (Fig. 5 A),
while no differences were observed in the number of Ly6C monocyte
subsets (Fig. 5 B, D–F), in the Ly6Chi/Ly6Cmed ratio (Fig. 5 C) and in
mean CD11b expression (Fig. 5 G–J). Only exception was the reduced
CD11b expression in Ly6Clo subset. This interesting observation sug-
gests distinct effects of LCAT- and ApoA1-deﬁciency in circulating
monocyte production.
Finally, to investigate if the reduced inﬂammatory phenotype of
circulating monocytes from Lcat−/− mice results in less inﬂammatory
tissue macrophages we performed gene expression analyses of com-
mon and M2 macrophage markers in liver tissue (Fig. 6 A). Livers of
Lcat−/− mice showed a consistent trend towards downregulation of
the common macrophage markers F4/80, Cd68 and Mcp1, and anFig. 1. Lcat−/−mice have mainly ApoE-containing HDL. Representative western blots for
ApoA-I, ApoE and ApoA-II in HDL isolated from pooled serum of WT (lanes 1–2) and
Lcat−/− (lanes 3–4) and Apoa1−/−mice (lanes 5–6). Total HDL (30 μg/μL protein) per ge-
notype was loaded in two technical replicates.increase in theM2markerMrc1, suggestive for a reduced inﬂammatory
phenotype of the liver.Moreover, peritonealmacrophages from Lcat−/−
mice showed a markedly reduced LPS-induced TNFα response com-
pared to macrophages from WT mice (Fig. 6 B). In line with the
observed phenotypic differences between Apoa1−/− and Lcat−/−
monocytes, peritoneal macrophages isolated from Apoa1−/− mice
showed an increased LPS-induced TNFα response (Fig. 6 C). Collective-
ly, these ﬁndings indicate that distinct mechanisms mediate the
increased systemic inﬂammatory response observed in Lcat−/− and
Apoa1−/−mice treated with LPS.
4. Discussion
It is well established that mature HDL possesses potent anti-
inﬂammatory properties and reduces LPS-induced inﬂammation
in vivo [14] and in vitro [28]. Since most studies have focused on
ApoA-I and mature HDL [14,15,29,30] the role of LCAT-mediated
maturation of HDL on its anti-inﬂammatory potential remains large-
ly unknown. To address this, we employed Lcat−/− mice that lack
mature HDL, and compared them to Apoa1−/−mice which lack clas-
sical HDL, andWT animals. We report that LCAT-deﬁciency increases
the systemic inﬂammatory response to LPS in vivo, impairs LPS-
neutralizing capacity of circulating HDL and increases blood mono-
cyte number. Importantly, this increased inﬂammatory response of
Lcat−/− mice is reversed by reintroducing LCAT expression. In
contrast to these pro-inﬂammatory effects, Lcat−/− mice have less
pro-inﬂammatory blood monocytes and peritoneal macrophages.
Finally, although both Lcat−/− and Apoa1−/− mice demonstrated a
comparable inﬂammatory response in vivo, distinct differences
were identiﬁed when comparing different aspects of the response
in vitro (summarized in Table 4).
The increased LPS-induced pro-inﬂammatory response observed
in vivo in Lcat−/−mice could be reproduced in vitro using whole blood
or serumof thesemice, indicating that alterations in serum components
are responsible for these effects. Indeed our further analyses indicated
that lack of mature HDL and the reduced LPS-neutralizing capacity of
the circulating immature HDL contribute, at least in part, to the in-
creased and prolonged inﬂammatory response of Lcat−/−mice in vivo.
HDL reduces LPS-induced inﬂammation by binding LPS that is released
in circulation, thereby inhibiting TLR4-mediated activation of macro-
phages [31] but also by facilitating the release of LPS that is already
bound to macrophages [21,32]. Thus, absence of mature HDL in
Lcat−/− mice logically contribute to reduced neutralization of LPS. In
our studies, the immature HDL that is still present in Lcat−/− mice
showed a reduced LPS-neutralizing capacity compared to HDL from
WT mice, indicating that structural changes in HDL determine its neu-
tralizing potential.
Our in vitro studieswith serumalso show that the LPS-induced TNFα
response was more pronounced with low concentrations of LCAT-
deﬁcient and ApoA-I-deﬁcient serum as compared to LPS alone. This
intriguing observation was also seen previously for other ‘pro-inﬂam-
matory’ genotypes [33], though the mechanistic interpretation to this
phenomenon is not clear at the present time. Another interesting obser-
vation is that lower concentrations of serum from Lcat−/− or Apoa1−/−
mice have a higher pro-inﬂammatory effect compared to higher serum
concentrations. Apparently, this is a known kinetic effect that relates to
the thermodynamic equilibrium:[Free-LPS] + [serum factors]
⇔[bound LPS], with a Kd = [bound LPS] / ([Free-LPS] × [serum fac-
tors]). Bound LPS is neutralized, while free LPS is the active one. The
more serum is added to the equilibrium (by increasing serum concen-
tration) the more the equilibrium shifts to the right, that is more LPS
is found in the bound (inactive) form, thereforemore LPS is neutralized.
In fact, high concentrations of serum factors, including for example the
abundantly present albumin, may act like a sink for LPS in vitro.
We excluded the involvement of a direct bridging function of LCAT
as addition of puriﬁed LCAT protein to LCAT-deﬁcient HDL did not
Fig. 2. LCAT-deﬁciency enhances the LPS-induced inﬂammatory response in vivo. LPS (100 μg/kg body weight) was intravenously injected in Lcat−/− andWTmice, and plas-
ma TNFα (A), GM-CSF (B), IFNγ (C), IL-2 (D), IL-12p70 (E) and IL-10 (F) were determined at the indicated time points. Values represent mean ± SEM (n = 10; pooled per 2
mice). * indicates P b 0.05, ** indicates P b 0.01 and *** indicates P b 0.001 vs WT mice. LPS-induced plasma TNFα levels of individual Lcat−/− (G) and Apoa1−/− mice
(H) were determined by ELISA. Values represent mean ± SEM (n = 6–10). * indicates P b 0.05 and ** indicates P b 0.01 vs WT mice. Lcat−/− mice were infected with
5 × 108 pfu of either AdGFP or AdLCAT and WT mice were infected with 5 × 108 pfu of AdGFP, and 3 days following infection all animals were intravenously injected
with LPS and plasma TNFα levels were determined (I). Values represent mean ± SEM (n = 5–6). * indicates P b 0.05 vs Lcat−/− mice treated with AdLCAT and # indicates
P b 0.05 vs WT mice treated with AdGFP.
Fig. 3. LCAT-deﬁciency enhances the LPS-induced inﬂammatory response of whole
blood ex vivo. Whole blood from Lcat−/− , Apoa1−/− and WT mice was diluted in
serum-free DMEM medium and subsequently incubated (18 h at 37 °C) without or
with LPS (1–10 ng/mL). Data are representative for 2 experiments and expressed as
mean ± SEM (n = 5). * indicates P b 0.05 vs WT blood.
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apparent LPS-binding motifs [26] in the amino acid sequence of LCAT.
Thus, it appears that LCAT does not affect directly the LPS-induced
TNFα-response. Particle geometry (discoidal vs. spherical) may be one
other reason for the observed phenotypic differences. Another contrib-
uting factor to the observed lack of neutralizing capacity of HDL from
Lcat−/− mice may be an altered protein cargo. Indeed, our analysis
shows lack of ApoA-I in HDL of Lcat−/− mice. This is in agreement
with dramatically lower ApoA-I plasma levels in Lcat−/− mice [34]
and humans [35]. In addition, HDL of Lcat−/−mice contains signiﬁcantly
higher amounts of ApoE compared to WT mice.
Finally, we show that circulatingmonocytes are increased in Lcat−/−
mice, a ﬁnding that could further explain the increased LPS-induced
pro-inﬂammatory response. Unexpectedly however, the inﬂammatory
potential of circulating monocytes and peritoneal macrophages was
attenuated. Apparently, the increase in the number of circulating mono-
cytes is explained by a marked increase in ‘mildly-inﬂammatory’ effector
Ly6Cmed cells, whereas the number of ‘pro-inﬂammatory’ Ly6Chi mono-
cytes was rather reduced. The reduced inﬂammatory status of the circu-
lating monocytes and macrophages in Lcat−/− mice was further
Fig. 4. LCAT-deﬁciency reduces the LPS-neutralizing capacity of serum and HDL in vitro. RAW 264.7 macrophages were incubated for 4 h without or with LPS (100 ng/mL) that was pre-
incubated (30min at 37 °C),with the indicated concentrations of serum from Lcat−/− (A) orApoa1−/− (B)mice and compared to serum fromWTmice. Similarly, RAW264.7macrophages
were incubated without or with isolated HDL, TRL or lipid-free proteins (all 10 μg protein/mL) ofWT, Lcat−/− (C) and Apoa1−/− (D)mice. RAW 264.7macrophages were also challenged
with LPS pre-incubated (100 ng/mL; 1 h at 37 °C) with HDL from Lcat−/− mice alone (0.01 μg/mL HDL-protein) or mixed with puriﬁed recombinant hLCAT protein (0.02 pg/mL,
representing plasma LCAT levels in mice) (E). Values represent mean ± SEM (n= 3–4). # indicates P b 0.05, ## indicates P b 0.01 and ### indicates P b 0.001 vs LPS alone; * indicates
P b 0.05, ** indicates P b 0.01 and *** indicates P b 0.001 vsWT serum/lipoproteins.
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the reduced LPS-induced cytokine response of peritoneal macrophages.
Recently, cholesterol efﬂux pathways have been highlighted as novel
regulators of myelopoiesis [37]. Mice with defective cholesterol efﬂux
(i.e. ATP-binding cassette transporter A1 (ABCA1) and G1 (ABCG1))
showed increased hematopoietic stem cell proliferation, mobilization,
and production of monocytes and neutrophils in bone marrow [38]. It is
thus possible that reduced cholesterol efﬂux in Lcat−/− mice, caused
either directly by the lack of LCAT-activity [39] or indirectly by the
reduced ApoA-I content of immature HDL, stimulates myelopoiesis that
in turn may account for the increased circulating monocyte. Our datathus indicate that LCAT-deﬁciency plays a very important role in mono-
cyte production and inﬂammatory phenotype of these immune cells,
though further studies are warranted.
To investigate the potential differences in the functional subsets
(i.e. M1 and M2) of hepatic macrophages in Lcat−/− and WT mice,
we used qRT-PCR to analyze the gene expression of some common
and M2 macrophage markers. This analysis showed a signiﬁcant
upregulation of the Mrc1 gene which encodes for the mannose re-
ceptor, present on the surface of macrophages and immature den-
dritic cells. MRC1 is implicated in phagocytosis, antigen
presentation, intracellular signaling, resolution of inﬂammation,
Fig. 5. LCAT-deﬁciency associates with an increased number but reduced inﬂammatory phenotype of circulating monocytes. Total circulating blood Cd11b+/Ly6C+ monocytes were
determined by ﬂow cytometry in Lcat−/− , Apoa1−/− and WT mice (A). Ly6Clo, Ly6Cmed and Ly6Chi within CD11b+ monocytes were gated and expressed as % of total white blood cells
(WBC; B). Ly6Chi/med ratiowas calculated as amarker of “anti-inﬂammatory” phenotype (C). Representative dot plots showing themonocyte subpopulations are shown (D–F). Represen-
tative histogramswith Cd11b expression (Mean Fluorescence Intensity) are shown (G-I) aswell asmean Cd11b expression of themonocytes subpopulations in the different genotypes (J).
Values represent mean ± SEM (n = 5). * indicates P b 0.05, ** indicates P b 0.01, and *** indicates P b 0.001 between groups.
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roles is in the resolution of inﬂammation, since it ensures the removal
of inﬂammatory agents (high-mannose oligosaccharides) from thecirculation at the late phases of inﬂammatory responses [41]. Overall
this analysis suggests a more anti-inﬂammatory and possibly regulatory
phenotype for hepatic macrophages in Lcat−/−mice.
Fig. 6. LCAT-deﬁciency associates with reduced hepatic inﬂammatory state and
dampened peritoneal macrophage responsiveness to LPS. Relative mRNA expression
levels of general and M2 macrophage markers in livers of Lcat‐/‐ mice as compared to
WT controls (A). Values represent mean ± SEM (n = 8). * indicates P b 0.05 between
groups. Thioglycollate-stimulated peritoneal macrophages from WT and Lcat−/−
(B) as well as from WT and Apoa1−/− mice (C) were isolated after peritoneal lavage,
washed, pooled and plated (8 × 105 cells/well in 24 well plates). The next day macro-
phages were incubated (4 h, 37 °C) without or with LPS (1–10 ng/mL) in DMEM. Data
are representative of 2 experiments and expressed as ng/mg cell protein and repre-
sent mean ± SEM (n = 4). * indicates P b 0.05, and ** indicates P b 0.01 vsWT group.
2114 P.-I. Petropoulou et al. / Biochimica et Biophysica Acta 1852 (2015) 2106–21155. Conclusions
Taken together, this study extends our current understanding on
the anti-inﬂammatory function of HDL showing that qualitative
changes in the lipoprotein particle may exert distinct effects on its
anti-inﬂammatory potential. We show that LCAT-deﬁciency triggersboth pro- and anti-inﬂammatory effects, however the net systemic
response of Lcat−/− mice to LPS challenge is pro-inﬂammatory.
Although ApoA-I-deﬁcient mice display a similar LPS-induced re-
sponse in vivo, the underlying mechanisms are mostly distinct. We
conclude that LCAT-mediated maturation of HDL plays a crucial
role in neutralizing circulating LPS and endotoxemia, but also an un-
expected role in determining the number and phenotype of mono-
cytes and macrophages.
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